American Association for Cancer Research
00085472can141643-sup-132624_2_supp_2782833_ngh6jl.png (1.54 MB)

Figure S5 from ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors

Download (1.54 MB)
posted on 2023-03-30, 23:23 authored by Loredana Cifaldi, Paolo Romania, Michela Falco, Silvia Lorenzi, Raffaella Meazza, Stefania Petrini, Marco Andreani, Daniela Pende, Franco Locatelli, Doriana Fruci

Supplementary Figure S5 shows surface expression of ligands for activating NK cell receptors on DAOY cells treated with ERAP1 inhibitor



The endoplasmic reticulum aminopeptidase ERAP1 regulates innate and adaptive immune responses by trimming peptides for presentation by MHC class I (MHC-I) molecules. Herein, we demonstrate that genetic or pharmacological inhibition of ERAP1 on human tumor cell lines perturbs their ability to engage several classes of inhibitory receptors by their specific ligands, including killer cell Ig-like receptors (KIR) by classical MHC-I–peptide (pMHC-I) complexes and the lectin-like receptor CD94-NKG2A by nonclassical pMHC-I complexes, in each case leading to natural killer (NK) cell killing. The protective effect of pMHC-I complexes could be restored in ERAP1-deficient settings by the addition of known high-affinity peptides, suggesting that ERAP1 was needed to positively modify the affinity of natural ligands. Notably, ERAP1 inhibition enhanced the ability of NK cells to kill freshly established human lymphoblastoid cell lines from autologous or allogeneic sources, thereby promoting NK cytotoxic activity against target cells that would not be expected because of KIR–KIR ligand matching. Overall, our results identify ERAP1 as a modifier to leverage immune functions that may improve the efficacy of NK cell–based approaches for cancer immunotherapy. Cancer Res; 75(5); 824–34. ©2015 AACR.

Usage metrics

    Cancer Research



    Ref. manager